5,059
Views
5
CrossRef citations to date
0
Altmetric
Research Articles

Reference-Based Multiple Imputation—What is the Right Variance and How to Estimate It

ORCID Icon
Pages 178-186 | Received 28 Apr 2021, Accepted 15 Sep 2021, Published online: 12 Nov 2021

References

  • Atkinson, A., Kenward, M. G., Clayton, T. and Carpenter, J. R. (2019), “Reference-Based Sensitivity Analysis for Time-to-Event Data,” Pharmaceutical Statistics, 18, 645–658. DOI: 10.1002/pst.1954.
  • Bartlett, J. W., and Hughes, R. A. (2020), “Bootstrap Inference for Multiple Imputation Under Uncongeniality and Misspecification,” Statistical Methods in Medical Research, 29, 3533–3546. DOI: 10.1177/0962280220932189.
  • Carpenter, J. R., Roger, J. H., and Kenward, M. G. (2013), “Analysis of Longitudinal Trials With Protocol Deviation: A Framework for Relevant, Accessible Assumptions, and Inference Via Multiple Imputation,” Journal of Biopharmaceutical Statistics 23, 1352–1371. DOI: 10.1080/10543406.2013.834911.
  • Carpenter, J., Roger, J., Cro, S., and Kenward, M. (2014), “Response to Comments by Seaman et al. on ‘Analysis of Longitudinal Trials With Protocol Deviation: A Framework for Relevant, Accessible Assumptions, and Inference Via Multiple Imputation,’ Journal of Biopharmaceutical Statistics, 23, 1352–1371,” Journal of Biopharmaceutical Statistics, 24, 1363–1369. DOI: 10.1080/10543406.2014.960085.
  • Cro, S., Carpenter, J. R., and Kenward, M. G. (2019), “Information-Anchored Sensitivity Analysis: Theory and Application,” Journal of the Royal Statistical Society, Series A, 182, 623–645. DOI: 10.1111/rssa.12423.
  • Daniels, M. J., and Hogan, J. W. (2008), Missing Data in Longitudinal Studies, Boca Raton, FL: Chapman & Hall/CRC.
  • Darken, P., Nyberg, J., Ballal, S., and Wright, D. (2020), “The Attributable Estimand: A New Approach to Account for Intercurrent Events,” Pharmaceutical Statistics, 19. DOI: 10.1002/pst.2019.
  • Diao, G., Liu, G. F., Zeng, D., Zhang, Y., Golm, G., Heyse, J. F., and Ibrahim, J. G. (2020), “Efficient Multiple Imputation for Sensitivity Analysis of Recurrent Events Data With Informative Censoring,” Statistics in Biopharmaceutical Research, 1–9, DOI: 10.1080/19466315.2020.1819403.
  • Gao, F., Liu, G. F., Zeng, D., Xu, L., Lin, B., Diao, G., Golm, G., Heyse, J. F., and Ibrahim, J. G. (2017), “Control-Based Imputation for Sensitivity Analyses in Informative Censoring for Recurrent Event Data,” Pharmaceutical Statistics, 16, 424–432. DOI: 10.1002/pst.1821.
  • Gao, F., Liu, G., Zeng, D., Diao, G., Heyse, J. F., and Ibrahim, J. G. (2017), “On Inference of Control-Based Imputation for Analysis of Repeated Binary Outcomes With Missing Data,” Journal of Biopharmaceutical Statistics, 27, 358–372. DOI: 10.1080/10543406.2017.1289957.
  • Keene, O. N., Roger, J. H., Hartley, B. F., and Kenward, M. G. (2014), “Missing Data Sensitivity Analysis for Recurrent Event Data Using Controlled Imputation,” Pharmaceutical Statistics, 13, 258–264. DOI: 10.1002/pst.1624.
  • Liu, G. F., and Pang, L. (2016), “On Analysis of Longitudinal Clinical Trials With Missing Data Using Reference-Based Imputation,” Journal of Biopharmaceutical Statistics, 26, 924–936. DOI: 10.1080/10543406.2015.1094810.
  • Lu, K. (2014), “An Analytic Method for the Placebo-Based Pattern-Mixture Model,” Statistics in Medicine, 33, 1134–1145. DOI: 10.1002/sim.6008.
  • Mallinckrodt, C., Bell, J., Liu, G., Ratitch, B., O’Kelly, M., Lipkovich, I., Singh, P., Xu, L., and Molenberghs, G. (2019), “Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9 (R1) Guidelines Into Practice,” Therapeutic Innovation & Regulatory Science, 54,353–364.
  • Meng, X. L. (1994), “Multiple-Imputation Inferences With Uncongenial Sources of Input” (with discussion), Statistical Science, 10, 538–573.
  • Quan, H., Qi, L., Luo, X., and Darchy, L. (2018), “Considerations of Multiple Imputation Approaches for Handling Missing Data in Clinical Trials,” Contemporary Clinical Trials, 70, 62–71. DOI: 10.1016/j.cct.2018.05.008.
  • Robins, J. M., and Wang, N. (2000), “Inference for Imputation Estimators,” Biometrika, 85, 113–124. DOI: 10.1093/biomet/87.1.113.
  • Seaman, S. R., White, I. R., and Leacy, F. P. (2014), “Comment on ‘Analysis of Longitudinal Trials With Protocol Deviations: A Framework for Relevant, Accessible Assumptions, and Inference Via Multiple Imputation’, by Carpenter, Roger, and Kenward,” Journal of Biopharmaceutical Statistics, 24, 1358–1362. DOI: 10.1080/10543406.2014.928306.
  • Shao, J., and Tu, D. (1995), The Jackknife and Bootstrap, Springer Science & Business Media. New York: Springer.
  • Tan, P.-T., Cro, S., Van Vogt, E., Szigeti, M. and Cornelius, V. R. (2021), “A Review of the Use of Controlled Multiple Imputation in Randomised Controlled Trials With Missing Outcome Data,” BMC Medical Research Methodology, 21, 1–17. DOI: 10.1186/s12874-021-01261-6.
  • Tang, Y. (2015), “Short Notes on Maximum Likelihood Inference for Control-Based Pattern-Mixture Models,” Pharmaceutical Statistics, 14, 395–399. DOI: 10.1002/pst.1698.
  • Tang, Y. (2017), “On the Multiple Imputation Variance Estimator for Control-Based and Delta-Adjusted Pattern Mixture Models,” Biometrics, 73, 1379–1387.
  • Tsiatis, A. A. (2006), Semiparametric Theory and Missing Data, New York: Springer.
  • von Hippel, P. T., and Bartlett, J. W. (2021), “Maximum Likelihood Multiple Imputation: Faster Imputations and Consistent Standard Errors Without Posterior Draws,” Statistical Science, 36, 400–420. DOI: 10.1214/20-STS793.
  • White, I., Joseph, R., and Best, N. (2020), “A Causal Modelling Framework for Reference-Based Imputation and Tipping Point Analysis in Clinical Trials With Quantitative Outcome,” Journal of Biopharmaceutical Statistics, 30, 334–350. DOI: 10.1080/10543406.2019.1684308.
  • Xie, X., and Meng, X.-L. (2017), “Dissecting Multiple Imputation From a Multi-Phase Inference Perspective: What Happens When God’s, Imputer’s and Analyst’s Models Are Uncongenial?” Statistica Sinica, 27, 1485–1545.
  • Zhang, Y., Golm, G., and Liu, G. (2020), “A Likelihood-Based Approach for the Analysis of Longitudinal Clinical Trials With Return-to-Baseline Imputation,” Statistics in Biosciences, 12, 23–36. DOI: 10.1007/s12561-020-09269-0.